LEADER 04801nam 22008415 450 001 9910300201603321 005 20200630160951.0 010 $a1-4471-4920-3 024 7 $a10.1007/978-1-4471-4920-0 035 $a(CKB)3710000000306034 035 $a(EBL)1964777 035 $a(SSID)ssj0001386826 035 $a(PQKBManifestationID)11833291 035 $a(PQKBTitleCode)TC0001386826 035 $a(PQKBWorkID)11374661 035 $a(PQKB)10743598 035 $a(DE-He213)978-1-4471-4920-0 035 $a(MiAaPQ)EBC1964777 035 $a(PPN)183085426 035 $a(EXLCZ)993710000000306034 100 $a20141129d2015 u| 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aTranslational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development $eA Focus on Early Phase Clinical Studies /$fedited by Andrew J. Krentz, Lutz Heinemann, Marcus Hompesch 205 $a1st ed. 2015. 210 1$aLondon :$cSpringer London :$cImprint: Springer,$d2015. 215 $a1 online resource (316 p.) 300 $aDescription based upon print version of record. 311 $a1-4471-4919-X 320 $aIncludes bibliographical references at the end of each chapters and index. 327 $a1. Review of physiology/pathophysiology -- 2. Methods for assessing insulin action in humans -- 3. Assessment of insulin secretion -- 4. Measurement of ectopic fat in liver and muscle using magnetic resonance spectroscopy -- 5. Isotopic tracers for the measurement of metabolic flux -- 6. Measuring food intake in clinical drug development -- 7. Measurement of energy expenditure -- 8. Assessment of body composition -- 9.  Assessment of cardiovascular safety of new diabetes drugs. 330 $aThis book aims to aid the selection of the most appropriate techniques for use in early phase (1 and 2) clinical studies of new drugs for diabetes, obesity, and related cardiometabolic disease. Clinical research methods for assessing the pharmacokinetics and pharmacodynamics of new diabetes drugs, e.g. the euglycaemic clamp technique, have become well-established in proof-of-mechanism studies; however, selection of the best techniques is by no means straightforward. This book will aid the understanding of the need for new pharmacotherapies for type 1 diabetes, type 2 diabetes, and obesity and the molecular targets of drugs currently in development.  Emerging technologies including the omics disciplines are considered together with practical and ethical issues of early phase clinical trials in subjects with cardiometabolic disorders. Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development  will be of interest to biomedical scientists, pharmacologists, academics involved in metabolic research and clinicians practicing in these specialties. 606 $aMedicine 606 $aInternal medicine 606 $aDiabetes 606 $aMetabolism$xDisorders 606 $aPharmacology 606 $aPharmaceutical technology 606 $aMedicine/Public Health, general$3https://scigraph.springernature.com/ontologies/product-market-codes/H00007 606 $aInternal Medicine$3https://scigraph.springernature.com/ontologies/product-market-codes/H33002 606 $aDiabetes$3https://scigraph.springernature.com/ontologies/product-market-codes/H33045 606 $aMetabolic Diseases$3https://scigraph.springernature.com/ontologies/product-market-codes/H33118 606 $aPharmacology/Toxicology$3https://scigraph.springernature.com/ontologies/product-market-codes/B21007 606 $aPharmaceutical Sciences/Technology$3https://scigraph.springernature.com/ontologies/product-market-codes/B21010 615 0$aMedicine. 615 0$aInternal medicine. 615 0$aDiabetes. 615 0$aMetabolism$xDisorders. 615 0$aPharmacology. 615 0$aPharmaceutical technology. 615 14$aMedicine/Public Health, general. 615 24$aInternal Medicine. 615 24$aDiabetes. 615 24$aMetabolic Diseases. 615 24$aPharmacology/Toxicology. 615 24$aPharmaceutical Sciences/Technology. 676 $a610 676 $a615 676 $a615.19 676 $a616 676 $a616.39 676 $a616.46 676 $a616462 702 $aKrentz$b Andrew J$4edt$4http://id.loc.gov/vocabulary/relators/edt 702 $aHeinemann$b Lutz$4edt$4http://id.loc.gov/vocabulary/relators/edt 702 $aHompesch$b Marcus$4edt$4http://id.loc.gov/vocabulary/relators/edt 906 $aBOOK 912 $a9910300201603321 996 $aTranslational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development$92512363 997 $aUNINA